Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

Summary

Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking. The primary aim of this project is to explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of a smoking cessation treatment for Veteran smokers living with HIV. The intervention uses mobile health and telehealth technology to personalize smoking cessation counseling and medications and provide relapse prevention text messaging.

Conditions

• Human Immunodeficiency Virus
• Smoking

Interventions

DRUG

Bupropion

Smoking cessation pharmacotherapy prescribed in accordance with package insert.

DRUG

Varenicline

Smoking cessation pharmacotherapy prescribed in accordance with package insert.

BEHAVIORAL

Cognitive Behavioral Therapy

Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention

DRUG

Nicotine Replacement Therapy

Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).

BEHAVIORAL

Relapse Prevention Text Messaging

Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.

Sponsors & Collaborators

• VA Office of Research and Development

  lead FED

Principal Investigators

• Sarah M. Wilson, PhD · Durham VA Medical Center, Durham, NC

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-11-18

Primary Completion

2021-07-15

Completion

2021-11-10

FDA Drug

Yes

Countries

• United States

Study Locations